Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ME2 | P23368 | 1/20 | 0.40 |
| ▸ | ME1 | P48163 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2466705 | 0.94 | MEN1 (0.46) | LMNAALOX15TSHRMAPK1OPRD1 | |
| SCHEMBL2471151 | 0.94 | OPRD1 (0.52) | LMNAALOX15TSHRMAPK1OPRD1 | |
| SCHEMBL2469075 | 0.91 | LMNA (0.46) | LMNAALOX15TSHRMAPK1OPRD1 | |
| SCHEMBL2471163 | 0.91 | GFER (0.47) | OPRD1MEN1KMT2AME2ME1 | |
| SCHEMBL2470225 | 0.90 | OPRD1 (0.49) | LMNAOPRD1MEN1KMT2AHSD11B1 | |
| SCHEMBL2491196 | 0.90 | LMNA (0.47) | LMNAOPRD1MEN1KMT2AOPRK1 | |
| SCHEMBL2465431 | 0.87 | OPRD1 (0.46) | TSHROPRD1KMT2AHSD11B1OPRK1 | |
| SCHEMBL2701396 | 0.86 | MEN1 (0.42) | OPRD1MEN1KMT2APOLBOPRK1 | |
| SCHEMBL13182951 | 0.86 | MEN1 (0.43) | LMNAOPRD1MEN1KMT2AMAPT | |
| SCHEMBL2473257 | 0.85 | MEN1 (0.45) | LMNAOPRD1MEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | LMNA 1070/4885ALOX15 2580/4885TSHR 2555/4885 |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | LMNA 1070/4885ALOX15 2580/4885TSHR 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.